Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 12-Month Low on Analyst Downgrade

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) hit a new 52-week low during trading on Tuesday after The Goldman Sachs Group downgraded the stock from a buy rating to a neutral rating. The Goldman Sachs Group now has a $25.00 price target on the stock, down from their previous price target of $61.00. Ultragenyx Pharmaceutical traded as low as $18.37 and last traded at $19.0540, with a volume of 1005279 shares trading hands. The stock had previously closed at $20.27.

A number of other equities research analysts have also weighed in on the stock. Barclays lowered their price objective on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, November 24th. Wells Fargo & Company lowered their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. HC Wainwright cut their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Finally, Leerink Partners decreased their price objective on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Fifteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $60.47.

Insider Buying and Selling

In related news, EVP Erik Harris sold 10,539 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $240,289.20. Following the transaction, the executive vice president directly owned 89,515 shares of the company’s stock, valued at $2,040,942. The trade was a 10.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Howard Horn sold 8,409 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.70, for a total transaction of $190,884.30. Following the sale, the chief financial officer owned 86,669 shares of the company’s stock, valued at $1,967,386.30. This represents a 8.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 104,958 shares of company stock valued at $2,394,858 over the last quarter. Company insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Conflicting short‑interest data released today shows reports of a “large increase” but the published figures read as zero/NaN, indicating the data is likely erroneous or incomplete — do not rely on these short‑interest numbers for trading signals.
• Negative Sentiment: Goldman Sachs downgraded RARE from buy to neutral and slashed the price target to $25 (from $61), citing concerns about setrusumab data — this analyst action raises downward pressure and may prompt further investor re‑rating. Goldman Sachs Downgrade
• Negative Sentiment: Multiple law firms (Rosen, Bragar Eagel & Squire, Robbins LLP, Bronstein Gewirtz & Grossman, Levi & Korsinsky, Pomerantz, Faruqi & Faruqi, etc.) issued notices about a securities‑fraud class action covering purchases from Aug 3, 2023–Dec 26, 2025 and an April 6, 2026 lead‑plaintiff deadline — increased litigation risk creates an overhang that can weigh on valuation and investor sentiment. Representative notices: Rosen (PR Newswire) Rosen Law Firm Notice, Bragar (GlobeNewsWire) Bragar Notice

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently modified their holdings of the business. Assetmark Inc. increased its holdings in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,024 shares during the period. Huntington National Bank lifted its holdings in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 393 shares during the period. Danske Bank A S purchased a new stake in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $39,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $55,000. Finally, Smartleaf Asset Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,169 shares during the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

The stock has a market capitalization of $1.92 billion, a PE ratio of -3.40 and a beta of 0.16. The company has a 50 day moving average price of $22.51 and a 200-day moving average price of $28.23.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The business had revenue of $207.28 million during the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business’s revenue was up 25.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.39) EPS. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.